Cytek Biosciences, Inc. cash flow to debt ratio of -19.74% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cytek Biosciences, Inc.'s free cash flow has decreased 140.13% from $21.85M last year to $-8.77M, signaling decreasing performance

Cytek Biosciences, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability.

Cytek Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.04 last year to 0.08 today, signaling weakened financials

Cytek Biosciences, Inc. has a net cash position, so leverage is healthy.

Cytek Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cytek Biosciences, Inc.'s profit margin has decreased (1.20K%) in the last year from -3.00% to -38.98%, signaling decreasing performance

Cytek Biosciences, Inc.'s short-term assets of $392.00M exceed its short-term liabilities of $77.80M

Cytek Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cytek Biosciences, Inc.'s return on equity of -23.53%, is lower than 15.00%, indicating bad performance

Cytek Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cytek Biosciences, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Cytek Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cytek Biosciences, Inc. has negative free cash flow, indicating cash burn

Cytek Biosciences, Inc.'s yearly earnings has decreased 1.01K% since last year from $-6.02M to $-66.54M, signaling decreasing performance

Cytek Biosciences, Inc.'s yearly revenue has increased 0.52% since last year from $200.45M to $201.49M, signaling increasing performance

ROIC -11.90% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cytek Biosciences, Inc.'s 3-year revenue CAGR of 7.10% is positive, indicating growing revenue over the past 3 years

Cytek Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Cytek Biosciences, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Cytek Biosciences, Inc. has insufficient data to evaluate this check.

Cytek Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cytek Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cytek Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cytek Biosciences, Inc. has insufficient data to evaluate this check.

Cytek Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cytek Biosciences, Inc. has a price-to-book ratio of 1.87x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cytek Biosciences, Inc. has a price-to-sales ratio of 2.92x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue